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Summary
Identification of small-molecule targets remains an im-
portant challenge for chemical genetics. We report an
approach for target identification and protein discov-
ery based on functional suppression of chemical inhi-
bition in vitro.We discovered pirl1, an inhibitor of actin
assembly, in a screen conducted with cytoplasmic ex-
tracts. Pirl1 was used to partially inhibit actin assem-
bly in the same assay, and concentrated biochemical
fractions of cytoplasmic extracts were added to find
activities that suppressed pirl1 inhibition. Two activi-
ties were detected, separately purified, and identified
as Arp2/3 complex and Cdc42/RhoGDI complex, both
known regulators of actin assembly. We show that
pirl1 directly inhibits activation of Cdc42/RhoGDI, but
that Arp2/3 complex represents a downstream sup-
pressor. This work introduces a general method for
using low-micromolar chemical inhibitors to identify
both inhibitor targets and other components of a sig-
naling pathway.
Introduction
Phenotypic screens for small-molecule inhibitors are
a powerful method by which to probe biological path-
ways, but they require subsequent identification of the
inhibitor target. When used as a protein discovery tool,
these screens have been called ‘‘forward chemical
genetics,’’ based on the analogy to traditional forward
genetics in which random mutants are screened for a
phenotype of interest and the mutated genes are subse-
quently identified [1]. Whereas genetics offers general
approaches for the identification of mutated genes,
such as complementation, the identification of the tar-
gets of small-molecule inhibitors, particularly low-mi-
cromolar ‘‘hits’’ often identified in phenotypic screens,
can be challenging [2, 3]. Consequently, diverse new ap-
proaches to small-molecule target identification are
greatly needed.
In addition to identifying mutated genes, traditional
genetics can also be used to discover other compo-
nents in a biological pathway of interest, for example,
*Correspondence: jeffrey.peterson@fccc.eduthrough high-copy suppressor screens. In this ap-
proach, individual genes from cDNA libraries are overex-
pressed to identify clones that suppress the original
mutation, restoring the wild-type phenotype. This can be
accomplished by overexpressing a wild-type copy of
the mutated gene but also by overexpressing other path-
way components downstream of the inactivated gene.
In the context of chemical genetics, high-copy sup-
pressor screens have been used successfully to identify
genes that, when overexpressed, confer resistance to
small molecules with antimicrobial and anticancer activ-
ities [4, 5], but this strategy is limited to compounds that
function in genetically tractable organisms. Phenotypic
screens for small-molecule inhibitors, however, are now
increasingly being conducted in cytoplasmic extracts
and other complex systems that are not amenable to
subsequent genetic screens [6, 7]. Inspired by the power
of genetic high-copy suppressor screens to identify
multiple components of a biological pathway in vivo,
we developed an analogous biochemical approach to
identify components of pathways that can be recapitu-
lated in vitro. We use chemical inhibitors as ‘‘mutations’’
and the addition of partially purified protein mixtures as
a means of ‘‘overexpressing’’ potential suppressors.
This biochemical suppression approach is conceptu-
ally related to the classic work of Rothman and col-
leagues in which the sulfhydryl alkylating agent N-ethyl-
maleimide (NEM) was used to inactivate proteins
required for Golgi membrane fusion in a cell-free system
[8]. The inactivated preparations were then functionally
complemented by the addition of partially purified pro-
tein fractions to allow an activity-based purification of
the proteins inactivated by NEM. This approach relied
on the relatively nonspecific and covalent modification
of any functionally relevant protein by NEM. By contrast,
the method we introduce here uses a noncovalent and
titratable small-molecule inhibitor, specifically identified
in a phenotypic screen, to partially inactivate its protein
target. Specific and partial inhibition of a protein in a sig-
naling pathway allowed for the identification not only of
the target of the inhibitor, but also of a downstream
component in the same pathway.
We used the biochemical suppression approach to
study a signaling pathway regulating actin polymer-
ization in cytoplasmic extracts of Xenopus laevis eggs
(Xenopus egg extracts) [9–11]. Liposomes containing
phosphatidylinositol 4,5-bisphosphate (PIP2 liposomes)
stimulate actin filament nucleation and polymerization in
the extract by activating the Rho family GTPase Cdc42.
Cdc42 then binds to two effectors, the transducer of
Cdc42-dependent actin assembly (Toca-1) and the neu-
ral-Wiskott-Aldrich syndrome protein (N-WASP), the
latter of which directly activates Arp2/3 complex [11].
Arp2/3 complex is a seven polypeptide protein assem-
bly that directly nucleates new actin filaments [12]. The
components of this pathway are evolutionarily con-
served and are thought to play central roles in cell motil-
ity and membrane trafficking [12].
In a screen for small-molecule inhibitors of PIP2-in-
duced actin polymerization [13, 14], we identified pirl1.
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then characterized and purified two activities that sup-
pressed inhibition by pirl1. These activities correspond
to Arp2/3 complex and Cdc42/RhoGDI (Rho guanine
nucleotide dissociation inhibitor) complex, two of the
protein complexes that mediate signaling from PIP2 to
actin. We present evidence that pirl1 acts by inhibiting
guanine nucleotide exchange on Cdc42, indicating that
the biochemical suppression strategy identified a direct
target of pirl1. In addition, we show that Arp2/3 complex
is not directly inhibited by pirl1, demonstrating that this
strategy also identified a downstream effector of the
pathway. These results illustrate a novel approach to
target identification that applies the power of genetic
high-copy suppressor screens to low-affinity chemical
inhibitors obtained in phenotypic high-throughput
screens conducted in vitro.
Results
Identification of Pirl1 and Characterization
of ‘‘Suppressor of Pirl1’’ Activity
A high-throughput screen for small-molecule inhibitors
of PIP2-induced actin polymerization [13, 14] identified
pirl1, a tetracyclic indole structurally similar to the
monoamine oxidase inhibitor pirlindole (Table 1). Pirl1
inhibited actin assembly induced by 10 mM PIP2 lipo-
somes in Xenopus egg extracts with an IC50 (dose re-
quired to inhibit the maximum polymerization rate by
50%) of 3 mM. Table 1 also presents structural deriva-
tives of pirl1 and their potency in this assay.
Using this screen, we previously reported the identi-
fication and characterization of wiskostatin, another
small-molecule inhibitor of PIP2-induced actin assembly
[13]. N-WASP was identified as the target of wiskostatin
by testing candidate proteins in in vitro reactions con-
taining purified proteins that reconstitute portions of
the PIP2-induced actin assembly pathway downstream
of Cdc42. In similar experiments, pirl1 failed to inhibit
in vitro reactions at doses that inhibit PIP2-induced actin
assembly in extracts. Consequently, we sought an alter-
native, less biased approach to identify the target of pirl1
in Xenopus egg extract.
Affinity-based methods for small-molecule target id-
entification are most likely to be successful with small-
molecule target affinities higher than the weak binding
implied by the low-micromolar IC50 observed with
pirl1. Furthermore, such methods as affinity labeling
and affinity chromatography generally favor abundant
targets [3]. We therefore approached the problem by
looking for proteins that functionally rescue the inhibited
pathway.
Genetic high-copy suppressor screens can identify
the wild-type allele of the mutated gene, but they can
also identify other components of the pathway that,
when overexpressed, overcome the phenotypic defect.
To adapt this concept to an in vitro assay, we consid-
ered that partially inhibiting a protein in a signaling path-
way with a small molecule is analogous to generating
a hypomorphic allele. Next, we reasoned that adding
concentrated protein fractions to introduce suppressor
activities is analogous to overexpressing proteins ge-
netically. These two steps form the basis for the
activity-based biochemical purification of suppressoractivities through iterative rounds of protein fraction-
ation and activity assays (Figure 1A).
We tested the feasibility of this approach in PIP2-in-
duced actin polymerization reactions inhibited by pirl1.
First, we partially inhibited Xenopus egg extract by
adding 5 mM pirl1 (Figure 1B; red trace), an inhibitor con-
centration that provides a wide dynamic range for mea-
suring suppression of inhibition while maintaining sensi-
tivity. Separately, we fractionated uninhibited extract by
cation exchange chromatography (SP Sepharose), con-
centrated the fractions, and added them to aliquots of
pirl1-inhibited extract. Fraction 9 potently stimulated
actin assembly despite pirl1 (Figure 1C).
We considered two trivial reasons why this fraction
might suppress inhibition by pirl1. First, an abundant
protein that binds the small molecule nonspecifically
might titrate pirl1 away from its relevant target. Alterna-
tively, a factor might appear to suppress pirl1 inhibition
by stimulating actin assembly through a PIP2-inde-
pendent mechanism. To address the first possibility,
fraction 9 or buffer was added to extract in the absence
of inhibitor, and actin assembly was induced by the ad-
dition of PIP2 liposomes. If the suppressor activity was
due to nonspecific titration of the inhibitor, it should
not affect actin polymerization kinetics in the absence
of pirl1. However, fraction 9 significantly enhanced actin
polymerization kinetics in the absence of pirl1 (Fig-
ure 1D; compare blue and red traces), indicating that
this fraction acts in a positive manner to promote actin
assembly rather than simply titrating pirl1 away from
its target.
To test if the suppressor activity in fraction 9 stimu-
lated actin assembly independently of the PIP2 pathway,
Table 1. Structure of Pirl1 and Related Compounds and
Corresponding IC50 in PIP2-Stimulated Actin Polymerization
Assays
Structure
IC50
(mM) Structure
IC50
(mM)
3 39
2 82
2 99
4 >100
12
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(A) Biochemical suppression of small-molecule inhibition. A small molecule is added to cytoplasmic extract to partially inhibit the activity of
interest. Separately, uninhibited extract is fractionated, and individual fractions are added to the inhibited extract. Fractions that suppress
compound inhibition in the activity assay are then fractionated further. The suppressor activity is purified by iterative rounds of fractionation
and activity assays.
(B) Pirl1 inhibits PIP2-induced actin polymerization in Xenopus egg extract. Extracts supplemented with pyrene-actin (HSS) were preincubated
with the indicated concentrations of pirl1 or DMSO vehicle, and 10 mM PIP2 liposomes were added (as indicated) to stimulate actin filament
nucleation. Actin polymerization was detected by the fluorescence increase of pyrene-actin upon incorporation into filaments.
(C) Assay for suppressor activity. The indicated concentrated fractions from uninhibited extract fractionated by cation exchange chromatog-
raphy were mixed with complete extract containing pirl1 (5 mM final concentration), and 10 mM PIP2 liposomes were added to induce actin
polymerization.
(D) The suppressor activity does not titrate pirl1 nonspecifically and is PIP2-dependent. Actin polymerization was monitored in uninhibited ex-
tracts to which fraction 9, PIP2 liposomes, or both were added.fraction 9 was added to a quiescent extract without PIP2
stimulation. No polymerization of actin due to fraction 9
was observed in the absence of PIP2 liposomes (Fig-
ure 1D; compare purple and green traces), demonstrat-
ing that the activity in fraction 9 was strictly dependent
on PIP2 to stimulate actin polymerization. Thus, fraction
9 appeared to contain a bona fide component of the
PIP2-dependent actin assembly pathway capable of
suppressing inhibition by pirl1. We therefore named
this activity SOP (suppressor of pirl1) and conducted a
large-scale biochemical purification to identify the pro-
tein or proteins responsible for the SOP activity.
Purification and Identification of SOP1 as Arp2/3
Complex and SOP2 as Cdc42/RhoGDI Complex
Xenopus egg extract was fractionated over SP Sephar-
ose, and fractions containing SOP activity were further
fractionated by Mono Q chromatography (Figure 2A). In-
terestingly, two independent, nonoverlapping peaks of
SOP activity were observed in fractions eluting from
the Mono Q column at 95 and 150 mM NaCl (data not
shown). We called these activities SOP1 and SOP2, re-
spectively, and we purified them independently.
SOP1-containing fractions from the Mono Q elution
were applied to a gel filtration column (Superdex 200),
and the elution profile revealed a major Abs280 nm peakmigrating atw240 kDa. SDS-PAGE analysis of the corre-
sponding fractions showed seven perfectly cofraction-
ating bands that correlated with SOP activity and had
molecular weights from 18 to 50 kDa, highly suggestive
of pure Arp2/3 complex (Figure 2B). Indeed, the identity
of these proteins as intact Arp2/3 complex was con-
firmed by their comigration with purified bovine brain
Arp2/3 complex (Figure 2C), by Western blotting with
antibodies to the Arp2 subunit (Figure 2C), and by in vitro
functional assays demonstrating that the SOP1-contain-
ing Superdex 200 fractions nucleate actin assembly
when stimulated by a peptide corresponding to the
C-terminal VCA domain of N-WASP (not shown), a
unique property of Arp2/3 complex [12]. Finally, native
Arp2/3 complex purified from bovine brain (shown in
Figure 3C) also exhibited SOP activity (Figure S1 in the
Supplemental Data available with this article online),
demonstrating that Xenopus Arp2/3 complex, and not
a minor contaminating protein, is responsible for SOP1
activity.
The identification of Arp2/3 complex as the SOP1 ac-
tivity suggested that Arp2/3 complex might be directly
inhibited by pirl1. However, pirl1 had no effect on VCA-
stimulated actin polymerization in Xenopus egg extract
(Figure 2D; compare red and blue traces) under condi-
tions in which PIP2-stimulated actin polymerization
Chemistry & Biology
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SOP1 as Arp2/3 Complex
(A) Purification scheme.
(B) Silver-stained SDS-PAGE of SOP1-con-
taining Superdex 200 fractions and corre-
sponding maximal actin polymerization rates
from pirl1-inhibited, PIP2-induced pyrene-
actin assays supplemented with pooled pairs
of adjacent column fractions (e.g., 37/38,
39/40), as in Figure 1C.
(C) Coomassie-stained SDS-PAGE of SOP1-
containing Superdex 200 fractions (pooled
fractions 38–42) and native bovine Arp2/3
complex. The lower panel shows a corre-
sponding Western blot for the Arp2 subunit
of Arp2/3 complex.
(D) Pirl1 does not directly inhibit Arp2/3 com-
plex. Xenopus egg extracts supplemented
with pyrene-actin were treated with 5 mM
pirl1 or DMSO vehicle and then stimulated
with either 10 mM PIP2 liposomes or 300 nM
GST-VCA to directly activate Arp2/3 complex.was inhibited (Figure 2D; compare green and purple
traces). Furthermore, the actin nucleation activity of nei-
ther purified Xenopus Arp2/3 complex nor bovine brain
Arp2/3 complex was affected by 25 mM pirl1 in purified
protein assays stimulated by the VCA polypeptide
(data not shown), suggesting, instead, that Arp2/3 com-
plex suppresses pirl1 inhibition by overcoming an up-
stream inhibited step through increased levels of a
downstream component. Yet, addition of excess
Arp2/3 complex to unstimulated extract did not sponta-
neously induce actin nucleation (Figure S1), indicating
that the activity of Arp2/3 complex still requires stimula-
tion by PIP2.
To purify the second SOP activity, SOP2-containing
fractions eluting from the Mono Q column were fraction-
ated by gel filtration and assayed for SOP activity (Fig-
ure 3A). Five silver-stained protein bands cofractionated
with SOP activity and eluted atw50 kDa from the Super-
dex 200 column (Figure 3A, asterisks). Mass spectrom-
etry analysis of tryptic digests of these five bands,
from highest to lowest apparent molecular weight
(MW), identified the following Xenopus laevis proteins:
arginyl aminopeptidase (MW = 70 kDa, 11 peptides,
15% coverage); protein phosphatase 5 (MW = 56 kDa,
5 peptides, 11% coverage); a mixture of eukaryotic
translation initiation factor 4H (MW = 26 kDa, 3 peptides,
22% coverage) and RAN binding protein 1 (MW = 24
kDa, 7 peptides, 24% coverage); Rho GDP-dissociation
inhibitor (RhoGDI) (MW = 23 kDa, four peptides, 30%
coverage); Cdc42 (MW = 21 kDa, 2 peptides, 13% cover-age) (Figure 3B shows sequence coverage for RhoGDI
and Cdc42). Quantitation by densitometry of the bands
corresponding to Cdc42 and RhoGDI in the fractions
from the Superdex 200 elution showed a striking corre-
lation between the abundance of these proteins and
SOP activity (Figure 3C), and Cdc42-specific Western
blot analysis of the SOP2 peak fraction revealed
a strongly reactive band that comigrated with recombi-
nant and bovine Cdc42 (Figure 3D), confirming the pres-
ence of Cdc42 in the SOP2-containing fractions.
The small GTPase Cdc42 is posttranslationally mod-
ified by a hydrophobic isoprenoid group and is kept
soluble in the cytoplasm by binding to RhoGDI [15].
RhoGDI inhibits Cdc42 signaling by preventing guanine
nucleotide exchange on Cdc42 and precluding inter-
actions with Cdc42 effectors [15]. Given the well estab-
lished role of Cdc42 in mediating PIP2-induced actin as-
sembly [9–11], the presence of both Cdc42 and RhoGDI
in the SOP2 peak fractions eluting from the gel filtration
column strongly suggested that the complex of these
two proteins might be responsible for suppressing
pirl1 inhibition of actin assembly in the extracts. Indeed,
recombinant Cdc42/RhoGDI complex suppressed pirl1
inhibition of PIP2-induced actin nucleation in a dose-de-
pendent manner (Figure 3E), demonstrating that Cdc42/
RhoGDI exhibits SOP activity. As for Arp2/3 complex,
the actin polymerization-promoting activity of recombi-
nant Cdc42/RhoGDI (as well as that of SOP2-containing
fractions) depended strictly on stimulation by PIP2 lipo-
somes (Figure S2).
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Since Cdc42 is inhibited by its interaction with RhoGDI
[15], activation of Cdc42/RhoGDI complex is required
for this complex to promote actin assembly. A necessary
event for activation is the exchange of GDP for GTP on
Cdc42 catalyzed by a guanine nucleotide exchange fac-
tor (GEF) [16]. However, which GEF is involved in PIP2-
Figure 3. SOP2 Is the Native Complex of Cdc42/RhoGDI
(A) Silver-stained SDS-PAGE of SOP2-containing Superdex 200
fractions and corresponding maximal actin polymerization rates
from pirl1-inhibited, PIP2-induced pyrene-actin assays supple-
mented with each fraction. Asterisks indicate proteins with elution
profiles correlating with SOP activity.
(B) Amino acid sequences of Xenopus Cdc42 and RhoGDI are
shown, and sequences of tryptic peptides identified by mass spec-
trometry in SOP2-containing fractions (51–54) are indicated in bold.
(C) Graph of SOP activity and densitometry of bands corresponding
to Cdc42 and RhoGDI in each Superdex 200 fraction (shown in [A]).
(D) Cdc42 Western blot analysis of recombinant Cdc42, two concen-
trations of partially purified, native bovine Cdc42/RhoGDI complex,
and SOP2-containing fraction 52.
(E) Recombinant Cdc42/RhoGDI complex exhibits SOP activity.
Xenopus egg extracts supplemented with pyrene-actin were prein-
cubated with 5 mM pirl1 and the indicated concentrations of recombi-
nant Cdc42/RhoGDI complex, and PIP2 liposomes were added to
induce actin polymerization.stimulated actin assembly in Xenopus egg extract is
not known.
To test if nucleotide exchange on Cdc42 is prevented
by pirl1, pirl1-inhibited extracts were stimulated by PIP2
liposomes in the presence of the nonhydrolyzable GTP
analog GTPgS to trap GTP bound Cdc42, which can
be captured by affinity isolation by using the p21 binding
domain of Pak kinase [17]. PIP2 stimulation caused a
dramatic activation of endogenous Cdc42 that was in-
hibited by pirl1 (Figure 4A). Importantly, the ability of
eight other pirl1 derivatives to inhibit PIP2-induced
Cdc42 activation perfectly correlated with their ability
to inhibit PIP2-induced actin assembly, implying that in-
hibition of Cdc42 activation is responsible for inhibition
of actin assembly.
Inhibition of nucleotide exchange on Cdc42/RhoGDI
complex by pirl1 could be direct or due to inhibition of
an upstream step in the pathway initiated by PIP2.
To discriminate between these possibilities, we con-
ducted in vitro guanine nucleotide exchange assays by
using recombinant Cdc42/RhoGDI complex, excess
free RhoGDI to minimize the basal rate of nucleotide ex-
change on Cdc42, and the isolated DH-PH domain of
Dbs, a well-characterized GEF for Cdc42 [18]. In this as-
say, Dbs catalyzed nucleotide exchange onto Cdc42
only upon PIP2 stimulation [19] (Figure 4B). Pirl1, but
not the inactive derivative 6, inhibited this nucleotide
exchange (Figure 4B).
Nucleotide exchange on Cdc42 can be artificially in-
duced in vitro by chelating magnesium with EDTA [20].
Because nucleotide release from Cdc42 requires disso-
ciation from RhoGDI, the kinetics of EDTA-mediated nu-
cleotide exchange on Cdc42/RhoGDI complex are likely
dictated by the dissociation rate of Cdc42/RhoGDI com-
plex itself. EDTA-mediated exchange was strictly PIP2
liposome dependent, suggesting that PIP2 liposomes
may promote dissociation of the complex [19] (Fig-
ure 4C). Importantly, pirl1, but not the inactive derivative
6, inhibited EDTA-mediated nucleotide exchange on
Cdc42 (Figures 4C and 4D), indicating that pirl1 directly
affects Cdc42/RhoGDI complex or its interaction with
PIP2 liposomes. Pirl1 did not affect EDTA-mediated nu-
cleotide exchange on nonprenylated Cdc42, which does
not form a complex with RhoGDI (Figure 4E), indicating
that pirl1 does not inhibit nucleotide release from or
binding to Cdc42 per se.
Thus, direct inhibition of PIP2-mediated guanine
nucleotide exchange on Cdc42/RhoGDI by pirl1 ac-
counts for the inhibition of actin polymerization in
PIP2-stimulated Xenopus egg extracts. These results
also establish the ability of the biochemical suppression
approach to identify signaling pathway components di-
rectly targeted by small-molecule inhibitors as well as
other components in the inhibited pathway.
Pirl1 Reversibly Inhibits Phorbol Ester-Induced
Membrane Ruffling
To test if pirl1 is cell permeable and perturbs actin dy-
namics in living cells, BS-C-1 cells were stimulated
with phorbol myristate acetate (PMA) to induce actin-de-
pendent membrane ruffling in the presence of DMSO,
pirl1, compound 1, or the inactive control compounds
5, 6, 7, or 8 (Figure 5; control compounds 5, 7, and 8
are not shown). Consistent with their activities in
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Xenopus Egg Extract and Guanine Nucleo-
tide Exchange on Cdc42/RhoGDI Complex
in Purified Protein Assays
(A) PIP2-mediated activation of Cdc42 in Xen-
opus egg extract is inhibited by pirl1. Extracts
were pretreated with different concentrations
of pirl1, related compounds (1–8, see Table 1),
or DMSO vehicle as indicated. After PIP2 lipo-
some stimulation in the presence of GTPgS,
activated Cdc42 was coprecipitated by using
the p21 binding domain of Pak kinase (GST-
PBD) bound to glutathione-agarose beads.
Cdc42 was detected by Western blotting.
(B) Pirl1 inhibits Dbs-mediated nucleotide
exchange on purified recombinant Cdc42/
RhoGDI complex. Cdc42/RhoGDI complex
(0.5 mM) was incubated with 1 mM RhoGDI;
30 nM DH-PH domain of Dbs; [35S]GTPgS;
100 mM PIP2 liposomes; and either 25 mM
pirl1, compound 6, or DMSO vehicle as indi-
cated. At each time point, protein bound
[35S]GTPgS was captured by filtration and
quantitated by scintillation counting.
(C) Pirl1 inhibits EDTA-mediated nucleotide
exchange on purified recombinant Cdc42/
RhoGDI. Assays were conducted as in (B), ex-
cept that4 mM EDTA was used instead of Dbs.
(D) Dose dependenceof pirl1 and compound6
inhibition of EDTA-mediated nucleotide ex-
change on purified Cdc42/RhoGDI complex.
Reactions like those in (C) were conducted
with the indicated concentrations of pirl1 or
compound 6, and protein bound GTPgS was
quantified after 3 min of incubation. Error
bars indicate standard error (n = 3).
(E) Pirl1 does not inhibit nucleotide exchange
on nonprenylated Cdc42. Assays were con-
ducted as in (C), except that soluble, nonpre-
nylated Cdc42 was used instead of Cdc42/
RhoGDI complex.Xenopus egg extracts, pirl1 and compound 1, but not the
inactive control compounds, prevented the formation of
actin-rich ruffles on the dorsal cell surface, whereas ac-
tin stress fibers, normally disrupted by PMA treatment
(Figure 5A, ‘‘PMA’’), remained intact. Quantitation of
this effect is shown in Figure 5B. Remarkably, the inhib-
itory effect of pirl1 did not require preincubation of the
cells with pirl1 prior to PMA stimulation, and removal of
pirl1 from the media restored the ability of treated cells
to respond to PMA (Figure 5, ‘‘Pirl1 washout’’). These re-
sults indicate that pirl1 is cell permeable, and that it can
reversibly inhibit PMA-induced membrane ruffling.
Discussion
The work presented here applies, for the first time, the
conceptual principles of a genetic high-copy suppres-
sor screen to an in vitro biochemical reaction partially in-
hibited by a small molecule. Using iterative rounds of
activity assays and biochemical fractionation, we identi-
fied two distinct protein complexes that, when added at
increased concentrations, suppress inhibition by pirl1,
a novel chemical inhibitor of the PIP2-dependent actin
assembly pathway. SOP1 was identified as the native
Xenopus Arp2/3 complex, and SOP2 was identified as
the native Xenopus Cdc42/RhoGDI complex. Both pro-
tein complexes are known mediators of signaling fromPIP2 to actin, validating this method for the discovery
of proteins mediating signaling pathways. Pirl1 did not
directly inhibit Arp2/3 complex function, suggesting
that it was identified as a SOP activity by virtue of acting
downstream of the inhibited component of the signaling
pathway. In contrast, pirl1 potently inhibited guanine
nucleotide exchange on Cdc42/RhoGDI complex, both
in extracts and in purified protein assays, indicating
that this complex is the inhibited target in the pathway.
Consistent with its ability to perturb actin filament nu-
cleation in Xenopus egg extract, pirl1 inhibited mem-
brane ruffling induced by PMA in live cells in a reversible
manner. Caution must be exercised, however, when in-
terpreting phenotypes induced by pirl1 in live cells until
its specificity and effectiveness at inhibiting Cdc42 are
established in future work. Other members of the Rho
family of small GTPases, for example, Rac and Rho,
also form complexes with and are regulated by RhoGDI,
and their activation could conceivably also be inhibited
by pirl1. Potential inhibition of these other GTPases,
however, does not conflict with identification of Cdc42/
RhoGDI as the relevant target of pirl1 by biochemical
suppression. In fact, one advantage of the biochemical
suppression strategy lies in its ability to identify targets
that are active in the pathway being studied, even if the
inhibitor also targets other proteins that are not func-
tionally relevant.
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(A) BS-C-1 cells were either fixed directly (unstimulated) or simultaneously treated for 15 min with 250 ng/ml phorbol myristate acetate (PMA)
and either DMSO vehicle (labeled ‘‘PMA’’), 50 mM pirl1, compound 1, or inactive control compound 6. Cells labeled ‘‘Pirl1 washout’’ were
treated for 15 min with 50 mM pirl1 alone, and then the media was removed and replaced with media lacking pirl1 for 1 hr prior to stimulation
with PMA as described above. All cells were fixed and stained with Alexa 488-labeled phalloidin to visualize the filamentous actin cytoskeleton.
The scale bar is 50 mm.
(B) Quantitative analysis of the experiment shown in (A). The percentage of cells exhibiting actin-rich membrane ruffles is shown for each con-
dition. The number of cells counted for each condition is shown beneath each bar.We cannot presently conclude that Cdc42 is the
relevant GTPase mediating inhibition of PMA-induced
membrane ruffling in BS-C-1 cells because the mecha-
nisms mediating PMA-induced ruffling are still not com-
pletely understood and may be cell-type specific.
Although experiments involving expression of domi-
nant-negative GTPases in a murine macrophage cell
line suggest that PMA-induced ruffling requires Cdc42
but not Rac1 [21], similar experiments in Swiss 3T3 cells
suggest that PMA-induced ruffling does require Rac1
[22, 23]. Notwithstanding the issue of specificity, our
studies introduce a novel, reversible reagent for probing
actin dynamics in living cells. These types of com-
pounds have historically played an important role in
the study of the cytoskeleton [24].
An important distinction between the biochemical
suppression strategy described here and traditional ge-
netic high-copy suppressor screens is that biochemical
suppression is mediated by completely native protein
forms as opposed to individual gene products. Indeed,
it is unlikely that overexpression of individual subunits
of either Arp2/3 complex or Cdc42/RhoGDI complex
would suppress pirl1 inhibition because of the impor-
tance of the integrity of the complexes for their function.
Thus, biochemical suppression offers the distinct ad-
vantage of identifying physiologically relevant proteincomplexes that constitute suppressor activities and
that are typically inaccessible to genetic approaches.
Our approach is also distinguished from the classic
work of Rothman and colleagues, who inactivated fac-
tors required for Golgi membrane fusion with the alkylat-
ing agent NEM to allow activity-based purification of
those factors by complementation [8]. NEM treatment
covalently modifies many free sulfhydryl groups, and,
consequently, it would be difficult to control the reaction
to only partially modify a particular target. Thus, in NEM-
treated cytosol, NEM-sensitive factors are completely
inactivated. By contrast, pirl1 is a noncovalent and re-
versible inhibitor, and it could be carefully titrated to
only partially inhibit Cdc42/RhoGDI in Xenopus egg ex-
tract. The importance of this distinction is established by
the fact that partial inhibition of Cdc42/RhoGDI complex
by pirl1 enabled the identification of Arp2/3 complex as
an SOP activity. The ability of Arp2/3 complex to sup-
press inhibition by pirl1 is strictly dependent on the pre-
sence of some residual Cdc42 activity owing to only par-
tial inhibition by pirl1. For instance, addition of Arp2/3
complex to unstimulated extracts (where Cdc42 activity
is completely absent) does not induce actin assembly,
even in the absence of pirl1. Thus, noncovalent, titrat-
able small-molecule inhibitors can be used to alter
rate-limiting steps in signaling pathways rather than
Chemistry & Biology
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nontarget suppressor activities.
Biochemical suppression is particularly suited for the
relatively low-affinity inhibitors typically identified in
phenotypic screens. For example, in order to achieve
the partial inhibition essential for detecting nontarget
suppressors, a high-affinity (e.g., low nanomolar IC50) in-
hibitor would have to be used at such a low concentra-
tion that it would likely be much more readily titrated
away nonspecifically by abundant proteins in biochem-
ical suppression assays. In this context, it is interesting
to note that neither of the two suppressor activities we
identified titrated away the inhibitor nonspecifically or
stimulated actin assembly by an unrelated mechanism.
Because the strategy requires only the ability to intro-
duce partially purified protein fractions into an assay of
interest, it should be widely applicable to phenotypic
screens conducted in extracts, complex mixtures, or
permeabilized cells [6, 7]. Such unbiased screens for
small-molecule inhibitors that disrupt a biological pro-
cess of interest are powerful discovery tools because,
having multiple potential targets, they allow those com-
ponents of a pathway that are most susceptible to
chemical inhibition to reveal themselves. In addition, cy-
toplasmic extracts can generally be prepared in large
scale at relatively low cost compared to the production
and purification of recombinant proteins for targeted
screening. Furthermore, because the purification of
suppressors is based on biochemical activity, even pro-
teins present at low abundance, but exhibiting measur-
able biological activity, can be identified. By contrast,
purification of protein targets on immobilized small-
molecule matrices is substantially biased by protein
abundance.
Finally, our results broadly suggest a strategy for
choosing targets for drug discovery. Rather than invest-
ing substantial time and effort in choosing and validating
a specific protein target in advance of high-throughput
screening, primary phenotypic screens can be used in
conjunction with target identification strategies such
as the biochemical suppression approach both to iden-
tify critical components of a signaling pathway of inter-
est in an unbiased way and to produce initial lead inhib-
itors. A second phase of targeted screening in vitro with
the purified target protein can then be used to identify
compounds of greater potency.
Significance
Identification of the targets of low-affinity small-mole-
cule inhibitors discovered in phenotypic screens is
a major challenge for chemical genetics. We present
a novel approach to target identification, inspired by
genetic high-copy suppressor screens, in which sup-
pressor activities are introduced as biochemical frac-
tions into partially inhibited in vitro reactions. We
call this strategy ‘‘biochemical suppression.’’ Using
pirl1, a novel compound identified by a screen for in-
hibitors of a phosphoinositide (PIP2)-dependent sig-
naling pathway regulating actin assembly, we identi-
fied two distinct suppressor activities and purified
them by iterative rounds of biochemical fractionation
and activity assays. One of these activities was the na-
tive complex of Cdc42 bound to RhoGDI, and the sec-ondwasArp2/3 complex. Both are known components
of the PIP2-dependent actin assembly pathway, thus
validating the approach. In vitro experiments estab-
lished that Cdc42/RhoGDI complex is a direct target
of pirl1, whereas Arp2/3 complex is a downstream
component of the pathway capable of relieving up-
stream inhibition of Cdc42/RhoGDI when added at
high concentrations. Thus, biochemical suppression,
like genetic high-copy suppressor screens, allows
for the identification of not only the functionally
perturbed protein in a biological pathway, but also of
other components of the pathway. This approach
can therefore be used as a protein discovery tool by
which to identify multiple components of a signaling
pathwaymediating a biological process of interest. Im-
portantly, the suppressor activities are introduced as
native protein forms rather than individual gene prod-
ucts, allowing for the identification of suppressor ac-
tivities composed of complexes of multiple proteins.
Furthermore, the biochemical suppression strategy
can, in principle, be used in any assay to which par-
tially purified biochemical fractions can be added
and, consequently, may be of broad utility. Finally,
we establish that pirl1 reversibly perturbs actin-depen-
dent membrane ruffling in live cells, and that it may
therefore be a versatile reagent with which to study
this complex process.
Experimental Procedures
Reagents
Pirl1 (8-Cyclopentyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]car-
bazole), compounds 1, 2, 3, and 6 were purchased from Chembridge
(SanDiego, CA). Compounds 5, 7, and 8were purchased from Chem-
navigator (San Diego, CA). The identity and purity (>95%) of pirl1
were confirmed by liquid chromatography/mass spectrometry (LC/
MS) and NMR. All compounds were solubilized in DMSO and stored
at 220ºC. Anti-Cdc42 antibodies were purchased from Transduc-
tion Labs, and anti-Arp2 antibodies were purchased from Santa
Cruz Biotechnology. Recombinant Cdc42/RhoGDI complex was
kindly provided by Drs. Greg Hoffman and Richard Cerione. For gua-
nine nucleotide exchange experiments, Cdc42/RhoGDI complex
was prepared as previously described [15]. A plasmid encoding
the His6-tagged DH-PH domain of Dbs was kindly provided by
Dr. John Sondek (UNC, Chapel Hill).
Actin Polymerization Assays in Xenopus Egg Extracts
PIP2 liposomes (4:48:48 PI[4,5]P2:phosphatidylcholine:phosphati-
dylinositol) were added to Xenopus egg extracts containing 2 mM
pyrene-actin and DMSO vehicle (1% final concentration) or small
molecule as previously described [14]. Pyrene fluorescence (excita-
tion 347 nm, emission 386 nm) was measured at 22ºC in a fluores-
cence spectrophotometer (Varian Cary Eclipse). Maximum polymer-
ization rates were determined as reported [13], by using a 1 min
sliding window across the entire time course. For IC50 determina-
tion, maximum polymerization rates were plotted as a function of
small-molecule concentration and fit to a sigmoidal dose-response
curve with variable slope (by using Prism 4.0). IC50 is defined as the
compound dose required to inhibit the maximum polymerization
rate by 50%. For assays of column fractions, the high-speed super-
natant of Xenopus egg extracts [14] (w8 mg/ml) containing 10 mM
pirl1 and pyrene-actin was diluted with an equal volume of 0.2 mM
ATP/CSF-XB (100 mM KCl, 0.1 mM CaCl2, 2 mM MgCl2, 10 mM po-
tassium HEPES [pH 7.7], 5 mM EGTA) 6 each protein fraction (pre-
viously dialyzed into CSF-XB) and then stimulated with PIP2 lipo-
somes.
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For preliminary characterization of the SOP activity, 4 ml high-speed
supernatant of Xenopus egg extract [14] (w8 mg/ml) was dialyzed
into 20 mM Tris (pH 7.6), 20 mM NaCl, 1 mM MgCl2, 1 mM DTT. Im-
mediately prior to fractionation, the pH was adjusted to 6.1 by the
addition of 0.1 volumes of 0.5 M PIPES (pH 6.1), and the high-speed
supernatant was fractionated over SP Sepharose (GE Healthcare).
Bound proteins were eluted over 8 column volumes in buffer S
(20 mM PIPES [pH 6.1], 20 mM NaCl, 1 mM DTT) with a linear NaCl
gradient from 20 mM to 1 M. Fractions were neutralized with 0.05
volumes of 1 M HEPES (pH 7.75) and were concentrated w11-fold
by centrifugal ultrafiltration prior to dialysis against CSF-XB/1 mM
DTT. Fraction volumes were normalized by the addition of CSF-
XB/1 mM DTT to the more concentrated fractions.
For large-scale purification of SOP1 and SOP2, low-speed Xeno-
pus egg extract [25] from 70 frogs was diluted 1:4 with 10 mM KCl,
0.1 mM CaCl2, 10 mM HEPES (pH 7.7), 5 mM EGTA before high-
speed centrifugation (3 hr at 40,000 rpm in a Beckman Type 45 Ti ro-
tor, followed by 4 hr at 28,000 rpm in a Beckman SW28 rotor). A total
of 1.25 g protein obtained in the supernatant (w200 ml) was acidified
by the addition of 0.1 volumes of 0.5 M PIPES (pH 6.1) and recentri-
fuged for 30 min at 40,000 rpm in a Beckman Type 45 Ti rotor. This
supernatant was applied to a 150 ml SP Sepharose HP column
and eluted over 2 liter in buffer S with a linear NaCl gradient from
20 mM to 1 M. Fractions (20 ml) were collected and neutralized
with 0.05 volumes of 1 M HEPES (pH 7.85). Samples of pooled, ad-
jacent fractions were concentrated w6.5-fold and dialyzed against
0.1 mM ATP/CSF-XB/1 mM DTT, and fraction volumes were normal-
ized as described above. Fractions containing SOP activity (21 mg
total protein, eluting at w200 mM NaCl) were pooled and dialyzed
against 20 mM Tris (pH 7.7), 40 mM NaCl, 1 mM DTT and applied
to a Mono Q HR 5/5 column (GE Healthcare) and eluted over 20 ml
in 20 mM Tris (pH 7.7), 20 mM NaCl, 1 mM DTT with a linear NaCl gra-
dient from 20 mM to 1 M. Samples of each fraction were assayed for
SOP activity directly. Fractions containing SOP1 activity (1.17 mg
total protein, eluting at 95 mM NaCl) and SOP2 activity (2.1 mg total
protein, eluting at 150 mM NaCl) were pooled separately and frac-
tionated independently over a calibrated Superdex 200 16/60 col-
umn (GE Healthcare) preequilibrated into CSF-XB/1 mM DTT.
Purified Arp2/3 Complex and Cdc42/RhoGDI Complex
Native bovine brain Arp2/3 complex was purified as described [13].
Recombinant Cdc42/RhoGDI complex and the GST fusion protein
with the VCA domain of N-WASP (GST-VCA) were expressed and
purified as described in [15] and [10], respectively.
Mass Spectrometry
Protein bands cofractionating with SOP2 activity were cut from
SDS-PAGE gels and subjected to in-gel trypsin digestion, and pep-
tides were identified by microcapillary LC/MS/MS analysis by the
Taplin Biological Mass Spectrometry Facility (Harvard Medical
School).
Cdc42 Activation Assays in Xenopus Egg Extract
A total of 200 ml Xenopus egg high-speed extract (8 mg/ml) was
brought to 0.2 mM ATP, 10 mM latrunculin B (to prevent actin poly-
merization), and compound or DMSO vehicle (1% final concentra-
tion) was added at the indicated concentration. Extracts were stim-
ulated by the addition of 20 mM GTPgS and/or 20 mM PIP2 liposomes
and incubated 10 min at room temperature as described [19]. GTP/
GTPgS bound Cdc42 was recovered by the addition of 18 mg
recombinant GST-p21 binding domain of Pak kinase (GST-PBD)
[17], incubation for an additional 10 min, followed by addition of lysis
buffer (100 mM Tris [pH 7.5], 2 mM MgCl2, 0.4 M NaCl, 2% NP40,
10% glycerol) and glutathione-agarose beads. After washes in 25
mM Tris (pH 7.5), 1 mM DTT, 30 mM MgCl2, 40 mM NaCl, 1%
NP40, and the same buffer lacking NP40, beads were analyzed by
SDS-PAGE and Western blotting with Cdc42-specific antibodies.
In Vitro Nucleotide Exchange Assays
Nucleotide exchange assays were performed as described [19].
Briefly, 10 mM [35S]GTPgS (Perkin Elmer, 2,000 dpm/pmol) was
added (at t = 0) to the mixture of pure components at the indicated
concentrations in reaction buffer (20 mM Tris [pH 7.5], 100 mMNaCl, 1 mM MgCl2, 1 mM DTT) at 25ºC. The reaction received com-
pound or an equivalent volume of DMSO (1%). At each time point,
15 ml aliquots of each reaction were diluted into 2 ml 4ºC termination
buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 10 mM MgCl2) and fil-
tered through nitrocellulose. The nitrocellulose was washed twice
with termination buffer, dried, and scintillation counted.
PMA-Induced Membrane Ruffling Assays
BS-C-1 cells were stimulated for 15 min by the addition of complete
media (10% fetal bovine serum in DMEM) containing 250 ng/ml
phorbol myristate actetate (PMA) and either 50 mM pirl1, compounds
1, 5, 6, 7, or 8, or DMSO vehicle. Unstimulated cells were treated with
an equivalent volume of DMSO (0.7% final concentration) only. Cells
were fixed in 4% formaldehyde in phosphate-buffered saline (PBS)
for 10 min at room temperature and then rinsed in PBS. For the
washout experiment, cells were treated for 15 min with 50 mM pirl1
and then washed into media without pirl1 for 1 hr prior to stimulation
with PMA and fixation as described above (Pirl1 washout, Figure 5).
After 10 min of permeabilization with 0.1% Triton X-100 in PBS
(PBS-T), cells were rinsed and blocked for 10 min in AbDil (PBS-T
containing 2% bovine serum albumin and 0.1% sodium azide). The
filamentous actin cytoskeleton was stained for 20 min with Alexa
488-phalloidin (Molecular Probes) at 1 mg/ml in AbDil. Epifloures-
cence images were captured with identical exposure times for
each sample on a CoolSnap ES camera (Photometrics) by using a
Nikon TE2000 microscope and a 603 oil immersion objective. The
percentage of cells exhibiting actin-rich membrane ruffles in the ex-
periment shown in Figure 5A was determined by a blinded observer
by counting total numbers of cells by using phase contrast imaging
prior to counting cells with prominent phalloidin-stained ruffles visu-
alized by epifluorescence.
Supplemental Data
Supplemental Data demonstrating that purified Arp2/3 complex ex-
hibits SOP activity and that Cdc42/RhoGDI complex requires PIP2
liposomes to activate actin polymerization in Xenopus egg extracts
are available at http://www.chembiol.com/cgi/content/full/13/4/
443/DC1/.
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